Baidu
map

SMC批准Xermelo进行类癌综合征腹泻

2018-06-24 MedSci MedSci原创

2017年9月,欧盟委员会批准了每日三次250 mg剂量的Xermelo®药物联合生长抑素类似物用于类癌综合征(CS)腹泻的治疗。该批准将允许Ipsen在欧盟、挪威和冰岛等28个成员国中销售Xermelo。近日,苏格兰药物联合会(SMC)正式宣布,类癌综合征(CS)腹泻患者现在可以在苏格兰接受Ipsen的Xermelo(Telotristat Ethyl)治疗

20179月,欧盟委员会批准了每日三次250 mg剂量的Xermelo®药物联合生长抑素类似物用于类癌综合征(CS)腹泻的治疗。该批准将允许Ipsen在欧盟、挪威和冰岛等28个成员国中销售Xermelo。近日,苏格兰药物联合会(SMC)正式宣布,类癌综合征(CS)腹泻患者现在可以在苏格兰接受IpsenXermeloTelotristat Ethyl)治疗。

与生长抑素类似物(SSA)联合的口服型Xermelo是治疗成年患者CS腹泻的治疗方法,这些患者接受SSA治疗后效果不佳,并且每天经历四次以上的排便。Xermelo曾被欧洲药品管理局授予孤儿药物名称,并获得欧洲委员会的认可。

神经内分泌肿瘤(NETs)是生长在身体神经内分泌系统中的罕见肿瘤,NETs的存在会破坏身体内的激素平衡,例如,NETs可能引发血清素过量产生,当血清素在体内大量存在时,它可以引起腹泻、潮红、喘鸣和心脏损伤等过程。而类癌瘤综合征是在神经内分泌肿瘤患者中偶尔见到的一组症状,大多数类癌瘤综合征发现于胃肠道而引起CS腹泻。


原始出处:

https://www.europeanpharmaceuticalreview.com/news/76408/xermelo-carcinoid-syndrome-diarrhoea/

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1937873, encodeId=54e8193e87342, content=<a href='/topic/show?id=e4281644634' target=_blank style='color:#2F92EE;'>#SMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16446, encryptionId=e4281644634, topicName=SMC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Aug 19 23:07:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955936, encodeId=d71a195593619, content=<a href='/topic/show?id=82b3e614798' target=_blank style='color:#2F92EE;'>#类癌综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76147, encryptionId=82b3e614798, topicName=类癌综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ae503, createdName=pps20019, createdTime=Sat Sep 22 05:07:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431249, encodeId=9960143124928, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jun 26 09:07:00 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-08-19 huhuaidong387
  2. [GetPortalCommentsPageByObjectIdResponse(id=1937873, encodeId=54e8193e87342, content=<a href='/topic/show?id=e4281644634' target=_blank style='color:#2F92EE;'>#SMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16446, encryptionId=e4281644634, topicName=SMC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Aug 19 23:07:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955936, encodeId=d71a195593619, content=<a href='/topic/show?id=82b3e614798' target=_blank style='color:#2F92EE;'>#类癌综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76147, encryptionId=82b3e614798, topicName=类癌综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ae503, createdName=pps20019, createdTime=Sat Sep 22 05:07:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431249, encodeId=9960143124928, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jun 26 09:07:00 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1937873, encodeId=54e8193e87342, content=<a href='/topic/show?id=e4281644634' target=_blank style='color:#2F92EE;'>#SMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16446, encryptionId=e4281644634, topicName=SMC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Aug 19 23:07:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955936, encodeId=d71a195593619, content=<a href='/topic/show?id=82b3e614798' target=_blank style='color:#2F92EE;'>#类癌综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76147, encryptionId=82b3e614798, topicName=类癌综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ae503, createdName=pps20019, createdTime=Sat Sep 22 05:07:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431249, encodeId=9960143124928, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jun 26 09:07:00 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-06-26 zhouqu_8
Baidu
map
Baidu
map
Baidu
map